pragma.vision Your technology observatory

Verification register Bio, Health & Neuro

Readiness verdict

Gedatolisib (Revtorpyk)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-07-21
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Ready

Primary summary from verified readiness

Confidence
58% · fresh
Computed at
2026-07-21T07:33:58.589065+00:00
Claimed
90

Public ambition and stated capability

Reported
76

Observed practitioner reporting

Verified
61

Independently supported evidence

Gap
+29

Claimed leads verified

Evidence strength Critical

Decision

What the current evidence supports

Human editorial judgment · 2026-07-21

Adopt with guardrails

Why
FDA-approved (2026-07-14) with a statistically decisive PFS benefit (HR 0.24, p<0.0001) and a genuinely novel pan-Class I PI3K + mTORC1/mTORC2 mechanism, but overall-survival data remain immature and the toxicity/administration burden (72% stomatitis, IV dosing) demands active guardrails before wider adoption framing.
Next
Track OS-maturation data readouts and real-world stomatitis-management/discontinuation-rate outcomes over the next 12-18 months before treating this as an established standard-of-care benchmark.

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
5
Tier 1
0
Tier 2
3
Tier 3
2
Supports
2
Contradicts
2
Context
1
Latest observed
2026-07-14

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-07-21 Reading moved from ready to ready.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.